Researchers conducted a Phase 2 clinical trial to compare two methods for measuring hair loss in patients with mild-to-moderate Alopecia Areata, defined as 50% or less hair loss. One method used centralized measurement from photographic images taken with standardized professional equipment, while the other relied on local ratings performed at the trial sites.
The results showed that the centralized rating system achieved good agreement and consistency. It produced margins of error that were 50% lower than the local rating system. However, substituting the local rating for the central rating would reduce the likelihood of achieving a statistically significant outcome by at least 50%, depending on the specific clinical response endpoint used.
No safety concerns were reported in this study, as adverse events and tolerability were not reported. The main reason to be careful is that potential inter-rater variability and margin of error in local scoring for mild-to-moderate Alopecia Areata may compromise results. Readers should understand that this study is in the early learning stage of clinical development, where centralized rating is most appropriate. This evidence does not yet support changing standard practice outside of this specific trial phase.